[Paclitaxel (Tesu) as a single agent in the treatment of breast cancer]

To evaluate the efficacy and the side effects of paclitaxel (Tesu) in breast cancer patients.

Tesu was administered at 175 mg/m2(170.9-210.8 mg/m2) to 22 patients with advanced breast cancer from March to July 1995. Tesu was given once in 21 days as one cycle, and the patients recieved 1-4 cycles (median: 3 cycles) of treatment.

Tesu induced 3 complete responses and 11 partial responses. The duration of remission was 2-7 months (median 3.5 months). The most frequent toxicities associated with Tesu administration were leukopenia, alopecia and myalgias.

Tesu as a single agent is effective in the treatment of breast cancer and the side effects are tolerable.